RXi Pharmaceuticals to Present at the 2017 Annual BIO Investor Forum

MARLBOROUGH, Mass., Oct. 11, 2017  /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical needs, announced today that Dr. Karen Bulock, Vice President of Research at RXi Pharmaceuticals, will present at 2017 Annual BIO Investor Forum. Dr. Bulock will discuss the Company's proprietary self-delivering RNAi (sd-rxRNA®) platform and demonstrate its broad applicability for cell-based immunotherapies to treat cancer.  The conference will take place October 17-18, 2017, at the Westin St. Francis Hotel in San Francisco, CA. 

Date: Wednesday, October 18, 2017          
Time: 2:45 pm Pacific
Track:  Platform for Therapeutics
Location: Elizabethan C

Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO

This international investor conference draws private equity, public investors, research analysts and industry executives from leading global pharmaceutical and established biotechnology companies focused on investment and business development opportunities in the life sciences industry.

The presentation will be webcast, and the link is available under the "Investors – Events and Presentations" section of the Company's website, www.rxipharma.com.

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a clinical-stage company developing innovative therapeutics that address significant unmet medical needs. Building on the pioneering discovery of RNAi, scientists at RXi have harnessed the naturally occurring RNAi process which can be used to "silence" or down-regulate the expression of a specific gene that may be overexpressed in a disease condition. RXi developed a robust RNAi therapeutic platform, including self-delivering RNA (sd-rxRNA®) compounds, that have the ability to highly selectively block the expression of any target in the genome, thus providing applicability to many therapeutic areas. Our current programs include dermatology, ophthalmology, and cell-based immunotherapy. RXi's extensive patent portfolio provides for multiple product and business development opportunities across a broad spectrum of therapeutic areas, and we actively pursue research collaborations, partnering and out-licensing opportunities with academia and pharmaceutical companies. For additional information, visit the Company's website, www.rxipharma.com. 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about: our ability to successfully develop RXI-109, Samcyprone™ and our other product candidates (collectively "our product candidates"); the future success of our clinical trials with our product candidates; the timing for the commencement and completion of clinical trials; our ability to enter into strategic partnerships and the future success of these strategic partnerships; and our ability to deploy our sd-rxRNA® technology through partnerships, as well as the prospects of these partnerships to provide positive returns. Forward-looking statements about expectations and development plans of RXi's product candidates and partnerships involve significant risks and uncertainties, including the following: risks that we may not be able to successfully develop and commercialize our product candidates; risks that product development and clinical studies may be delayed, not proceed as planned and/or be subject to significant cost over-runs; risks related to the development and commercialization of products by competitors; risks related to our ability to control the timing and terms of collaborations with third parties; and risks that other companies or organizations may assert patent rights preventing us from developing or commercializing our product candidates. Additional risks are detailed in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors."  Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.

Contact

RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646

SOURCE RXi Pharmaceuticals Corporation

Related Links

http://www.rxipharma.com